From Past to Present: The Evolution of Pharmacologic Therapies for Eosinophilic Esophagitis.

Within the evolving landscape of eosinophilic esophagitis (EoE) management are multiple pharmacologic treatment modalities, including proton pump inhibitors (PPIs), swallowed topical corticosteroids, and novel biologic agents. Studies to date on PPIs and corticosteroids have provided valuable insights into how to define the disease, and recently approved biologic therapies are heralding a new era of EoE management. Although progress has been made in treating this complex inflammatory, fibrostenotic disease and in understanding its pathophysiology, several knowledge gaps persist and continue to be investigated. In addition, unknowns exist regarding the long-term safety and efficacy of new EoE treatments and how to position therapies in diverse patient populations. This article aims to provide historical context for the current landscape of pharmacologic treatments in EoE and perspectives on how future development may improve understanding and management of this complex disease.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2025-05-01
Citations
1
Primary Topic
Eosinophilic Esophagitis
Type
article
Field-Weighted Citation Impact
2.01
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

From Past to Present: The Evolution of Pharmacologic Therapies for Eosinophilic Esophagitis.

Joy W. Chang, Susie Min
1 citations
PubMed
Eosinophilic Esophagitis
2.01
article

From Past to Present: The Evolution of Pharmacologic Therapies for Eosinophilic Esophagitis.

Joy W. Chang, Susie Min
article en
1 citations

Abstract

Within the evolving landscape of eosinophilic esophagitis (EoE) management are multiple pharmacologic treatment modalities, including proton pump inhibitors (PPIs), swallowed topical corticosteroids, and novel biologic agents. Studies to date on PPIs and corticosteroids have provided valuable insights into how to define the disease, and recently approved biologic therapies are heralding a new era of EoE management. Although progress has been made in treating this complex inflammatory, fibrostenotic disease and in understanding its pathophysiology, several knowledge gaps persist and continue to be investigated. In addition, unknowns exist regarding the long-term safety and efficacy of new EoE treatments and how to position therapies in diverse patient populations. This article aims to provide historical context for the current landscape of pharmacologic treatments in EoE and perspectives on how future development may improve understanding and management of this complex disease.

PubMedVol. 21(5)
University of Michigan (US)
Openalex Percentile: Top 15%
Eosinophilic Esophagitis
2.01
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

From Past to Present: The Evolution of Pharmacologic Therapies for Eosinophilic Esophagitis. — Joy W. Chang, Susie Min · PubMed (2025) | TGRS Research Map | TGRS